Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Research article

Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia

Authors: Daniel Eriksson, David Goldsmith, Siguroli Teitsson, James Jackson, Floortje van Nooten

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

Deteriorating renal function in chronic kidney disease (CKD) patients is commonly associated with reduced haemoglobin levels, adding to the already considerable humanistic burden of CKD. This analysis evaluated the impact of anaemia on disease burden in patients with CKD stages 3–4, and in those on dialysis.

Methods

This was a descriptive, cross-sectional analysis of European data from an Adelphi CKD Disease-Specific Programme. This programme collected data from patients and their treating nephrologists/endocrinologists; patient- and physician-reported data were matched for each patient. Health-related quality of life (HRQoL) data were obtained through patient completion of the EQ-5D, SF-12 and KDQOL-36. Additional information was obtained via physician reporting of patient symptoms, and patients’ reports of impaired activity. Anaemia was defined by haemoglobin level and/or current use of erythropoiesis stimulating agents.

Results

Significant, but modest Spearman’s rank correlations were observed between haemoglobin levels and extent of HRQoL impairment, regardless of instrument used (range 0.19–0.23; all P-values < 0.0001). When stratified by anaemia status, impairment was consistently lower for anaemic than non-anaemic CKD patients across measurement scales (e.g. EQ-5D index value [standard deviation {SD}] 0.72 [0.31] vs 0.83 [0.23], respectively; P < 0.0001). Physician-reported patient tiredness was associated with increased disease burden at all levels of CKD studied (total EQ-5D index value [SD] in patients reporting no tiredness vs tiredness 0.81 [0.26] vs 0.70 [0.30] respectively; P < 0.0001) with P < 0.0001 for no tiredness vs tiredness at all stages of CKD. The presence of anaemia was associated with impaired activity levels at CKD stages 3 (37.5 % vs 28.4 %, respectively; P = 0.0044) and 4 (48.1 % vs 39.9 %, respectively; P = 0.0292), and in patients on dialysis (52.0 % vs 45.0 %, respectively; P = 0.0732).

Conclusions

The analysis found that CKD patients with anaemia typically had a lower HRQoL than those without anaemia. The impairment correlated with anaemia was more apparent in non-dialysis patients with CKD stages 3 or 4 than in those receiving dialysis. Coexisting CKD and anaemia may have an impact on patient HRQoL similar to other chronic conditions such as diabetes, epilepsy or certain forms of cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10(1):42–53.CrossRefPubMed Cheng CK, Chan J, Cembrowski GS, van Assendelft OW. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Lab Hematol. 2004;10(1):42–53.CrossRefPubMed
4.
go back to reference Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37(2):395–402.CrossRefPubMed Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37(2):395–402.CrossRefPubMed
5.
go back to reference Singh NP, Sahni V, Wadhwa A, Garg S, Bajaj SK, Kohli R, et al. Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial Int. 2006;10(3):267–73.CrossRefPubMed Singh NP, Sahni V, Wadhwa A, Garg S, Bajaj SK, Kohli R, et al. Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial Int. 2006;10(3):267–73.CrossRefPubMed
6.
go back to reference Dousdampanis P, Trigka K, Fourtounas C. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications. Saudi J Kidney Dis Transpl. 2014;25(3):552–7.CrossRefPubMed Dousdampanis P, Trigka K, Fourtounas C. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications. Saudi J Kidney Dis Transpl. 2014;25(3):552–7.CrossRefPubMed
7.
go back to reference Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl. 2013;24(3):519–26.CrossRefPubMed Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl. 2013;24(3):519–26.CrossRefPubMed
8.
go back to reference Bailey RA, Reardon G, Wasserman MR, McKenzie RS, Hord RS. Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the minimum data Set in long-term care residents. Health Qual Life Outcomes. 2012;10:129.CrossRefPubMedPubMedCentral Bailey RA, Reardon G, Wasserman MR, McKenzie RS, Hord RS. Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the minimum data Set in long-term care residents. Health Qual Life Outcomes. 2012;10:129.CrossRefPubMedPubMedCentral
9.
go back to reference Rizzo M, Iheanacho I, Van Nooten F, Goldsmith D. A systematic literature review of the humanistic burden of anaemia associated with chronic kidney disease. Amsterdam: ERA-EDTA; 2014. Poster#MP198. Rizzo M, Iheanacho I, Van Nooten F, Goldsmith D. A systematic literature review of the humanistic burden of anaemia associated with chronic kidney disease. Amsterdam: ERA-EDTA; 2014. Poster#MP198.
10.
go back to reference Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed
12.
go back to reference Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329–38.CrossRefPubMed Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329–38.CrossRefPubMed
15.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed
16.
go back to reference Jha V, Wang AY, Wang H. The impact of CKD identification in large countries: the burden of illness. Nephrol Dial Transplant. 2012;27 Suppl 3:iii32–8.CrossRefPubMed Jha V, Wang AY, Wang H. The impact of CKD identification in large countries: the burden of illness. Nephrol Dial Transplant. 2012;27 Suppl 3:iii32–8.CrossRefPubMed
17.
go back to reference McIntyre CW, Goldsmith DJ. Ischemic brain injury in hemodialysis patients: which is more dangerous, hypertension or intradialytic hypotension? Kidney Int. 2015;87(6):1109–15.CrossRefPubMed McIntyre CW, Goldsmith DJ. Ischemic brain injury in hemodialysis patients: which is more dangerous, hypertension or intradialytic hypotension? Kidney Int. 2015;87(6):1109–15.CrossRefPubMed
18.
go back to reference Pulignano G, Del SD, Di LA, Tinti MD, Tarantini L, Cioffi G, et al. Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. J Cardiovasc Med (Hagerstown). 2014;15(6):481–90. Pulignano G, Del SD, Di LA, Tinti MD, Tarantini L, Cioffi G, et al. Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. J Cardiovasc Med (Hagerstown). 2014;15(6):481–90.
19.
go back to reference Zoppini G, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis. 2010;210(2):575–80.CrossRefPubMed Zoppini G, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis. 2010;210(2):575–80.CrossRefPubMed
20.
go back to reference Drueke TB, Locatelli F, Clyne N, Eckardt KU, MacDougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.CrossRefPubMed Drueke TB, Locatelli F, Clyne N, Eckardt KU, MacDougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.CrossRefPubMed
21.
go back to reference Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin Alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRefPubMed Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin Alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRefPubMed
22.
go back to reference Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, Eckardt KU, De ZD, et al. A trial of darbepoetin Alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRefPubMed Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, Eckardt KU, De ZD, et al. A trial of darbepoetin Alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRefPubMed
23.
go back to reference Goldsmith D, Covic A. Time to reconsider evidence for anaemia treatment (TREAT) = essential safety arguments (ESA). Nephrol Dial Transplant. 2010;25(6):1734–7.CrossRefPubMed Goldsmith D, Covic A. Time to reconsider evidence for anaemia treatment (TREAT) = essential safety arguments (ESA). Nephrol Dial Transplant. 2010;25(6):1734–7.CrossRefPubMed
24.
go back to reference Peters M, Crocker H, Dummett S, Jenkinson C, Doll H, Fitzpatrick R. Change in health status in long-term conditions over a one year period: a cohort survey using patient-reported outcome measures. Health Qual Life Outcomes. 2014;12:123.CrossRefPubMedPubMedCentral Peters M, Crocker H, Dummett S, Jenkinson C, Doll H, Fitzpatrick R. Change in health status in long-term conditions over a one year period: a cohort survey using patient-reported outcome measures. Health Qual Life Outcomes. 2014;12:123.CrossRefPubMedPubMedCentral
25.
go back to reference Samp JC, Perry R, Piercy J, Wood R, Baran RW. Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clin Res Hepatol Gastroenterol. 2015;39(3):307–14.CrossRefPubMed Samp JC, Perry R, Piercy J, Wood R, Baran RW. Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clin Res Hepatol Gastroenterol. 2015;39(3):307–14.CrossRefPubMed
26.
go back to reference Stein D, Joulain F, Naoshy S, Iqbal U, Muszbek N, Payne KA, et al. Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the united kingdom and the Netherlands. Int J Colorectal Dis. 2014;29(10):1203–10.CrossRefPubMed Stein D, Joulain F, Naoshy S, Iqbal U, Muszbek N, Payne KA, et al. Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the united kingdom and the Netherlands. Int J Colorectal Dis. 2014;29(10):1203–10.CrossRefPubMed
27.
go back to reference Hernandez AM, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(5):944–50.CrossRef Hernandez AM, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(5):944–50.CrossRef
Metadata
Title
Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
Authors
Daniel Eriksson
David Goldsmith
Siguroli Teitsson
James Jackson
Floortje van Nooten
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0312-9

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue